Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

The view beyond venture capital

Nature Biotechnology volume 32, pages 15–23 (2014)Cite this article

Subjects

Fundraising is an integral part of almost every young biotech's business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The life science investor landscape.
Figure 2: Examples of investor diversity in fundraising for early-stage life science companies.

References

  1. Mulcahy, D., Weeks, B. & Bradley, H.S. We have met the enemy... and he is us. Ewing Marion Kauffman Foundation, http://www.kauffman.org/∼/media/kauffman_org/research%20reports%20and%20covers/2012 /05/we%20have%20met%20the%20enemy%20and%20he%20is%20us(1).pdf (2012).

    Google Scholar 

  2. Ewing Marion Kauffman Foundation. Institutional limited partners must accept blame for poor long-term returns from venture capital, says new Kauffman report. Ewing Marion Kauffman Foundation, http://www.kauffman.org/newsroom/2012/07/institutional-limited-partners-must-accept-blame-for-poor-longterm-returns-from-venture-capital-says-new-kauffman-report (2012).

  3. PricewaterhouseCoopers. Life sciences venture capital funding drops 14% during 2012, according to the MoneyTree report. PricewaterhouseCoopers, http://www.pwc.com/us/en/press-releases/2013/2q-life-sciences-moneytree.jhtml (2013).

  4. Timmerman, L. Who's still active among the early-stage biotech VCs? Xconomy, http://www.xconomy.com/national/2012/07/02/whos-still-active-among-the-early-stage-biotech-vcs (2012).

    Google Scholar 

  5. PitchBook. 4Q 2013 Venture Capital Valuations & Trends Report. PitchBook, http://pitchbook.com/4Q2013_VC_Valuations_and_Trends_Report.html (2013).

  6. Ledford, H. Biotechnology: the start-up engine. Nature 501, 476–478 (2013).

    Article  CAS  Google Scholar 

  7. von Krogh, G., Battistini, B., Pachidou, F. & Baschera, P. The changing face of corporate venturing in biotechnology. Nat. Biotechnol. 30, 911–915 (2012).

    Article  CAS  Google Scholar 

  8. Angel Resource Institute & Silicon Valley Bank. 2012 Halo report: angel group update year in review. Angel Resource Institute, http://www.angelresourceinstitute.org/research/halo-report.aspx#2012HaloReport (2013).

  9. Beylin, D., Chrisman, C.J. & Weingarten, M. Granting you success. Nat. Biotechnol. 29, 567–570 (2011).

    CAS  PubMed  Google Scholar 

  10. US National Institutes of Health. Estimates of funding for various research, condition, and disease categories. U.S. National Institutes of Health, http://report.nih.gov/categorical_spending.aspx (2013).

  11. Laursen, L. Grant applications: find me the money. Nature 486, 559–561 (2012).

    Article  CAS  Google Scholar 

  12. Cromwell Schmisseur LLC. Information and observations on state venture capital programs. U.S. Department of the Treasury, http://www.treasury.gov/resource-center/sb-programs/Documents/VC%20Report.pdf (2013).

  13. FasterCures. Honest brokers for cures: how venture philanthropy groups are changing biomedical research. FasterCures, http://www.fastercures.org/assets/Uploads/PDF/HonestBrokers.pdf (2013).

  14. Senior, M. Family offices bolster early-stage financing. Nat. Biotechnol. 31, 473–475 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Maximilian Klietmann, Danielle Silva and Lucy Parkinson of Life Science Nation for research on this article. The authors would also like to thank the following individuals for their time and discussions: Vincent Miles, partner at Abingworth Life Science; Susanna Ling, associate director at the Milken Institute; John Walter, CEO at the Leukemia and Lymphoma Society; Melinda Richter, CEO at Prescience International and head of operations at Janssen Labs; Todd Sherer, CEO at the Michael J. Fox Foundation; and Ram May-Ron, managing partner at FreeMind Group.

Author information

Authors and Affiliations

  1. Dennis Ford is founder and CEO of Life Science Nation, Boston, Massachusetts, USA.,

    Dennis Ford

  2. Barbara Nelsen is founder of Nelsen Biomedical, St. Paul, Minnesota, USA.,

    Barbara Nelsen

Authors
  1. Dennis Ford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Nelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Dennis Ford or Barbara Nelsen.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ford, D., Nelsen, B. The view beyond venture capital. Nat Biotechnol 32, 15–23 (2014). https://doi.org/10.1038/nbt.2780

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2780

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research